Results 271 to 280 of about 286,011 (299)
Some of the next articles are maybe not open access.
Inflammation in Pulmonary Arterial Hypertension
2021Pulmonary artery hypertension (PAH) is a devastating cardiopulmonary disease characterized by vascular remodeling and obliteration of the precapillary pulmonary arterioles. Alterations in the structure and function of pulmonary vessels result in the resistance of blood flow and can progress to right-sided heart failure, causing significant morbidity ...
Timothy, Klouda, Ke, Yuan
openaire +2 more sources
Epoprostenol in pulmonary arterial hypertension
Expert Opinion on Drug Metabolism & Toxicology, 2008Pulmonary arterial hypertension (PAH) is a devastating disease leading to right heart failure and death in a relatively young patient population. In recent years novel PAH specific therapies have become available.To determine the place of epoprostenol in current PAH treatment strategies.An extensive Medline search was performed to evaluate the use of ...
Jacobs, W., Vonk Noordegraaf, A.
openaire +3 more sources
Sildenafil for Pulmonary Arterial Hypertension
American Journal of Therapeutics, 2019Pulmonary hypertension is a life-threatening illness with debilitating physical and emotional consequences. The progression of this devastating disease is characterized by a continuous increase in pulmonary vascular resistance, which results in elevated pulmonary artery pressure and leads to right heart failure.
Bhogal, Sukhdeep +5 more
openaire +3 more sources
Ambrisentan for Pulmonary Arterial Hypertension
Future Cardiology, 2005Endothelin receptor antagonists (ERAs) are an important class of agents used for the treatment of pulmonary arterial hypertension (PAH). Ambrisentan is an oral, once-daily, endothelin type-A receptor (ETA)-selective, propanoic acid class ERA under clinical investigation for the treatment of PAH.
Lewis J, Rubin +2 more
openaire +2 more sources
Pulmonary Arterial Hypertension in Portal Hypertension
Clinics in Gastroenterology, 1985Frequence d'estimation difficile; hypertension pulmonaire due a la cirrhose de differentes origines ou consequence d'anastomose porto-cave. Anatomopathologie des vaisseaux pulmonaires. Nature de l'hypertension portale. Etude clinique.
openaire +2 more sources
Pulmonary Arterial Hypertension: An Overview
Seminars in Cardiothoracic and Vascular Anesthesia, 2007Pulmonary arterial hypertension (PAH) was first described over 100 years ago, but a thorough understanding of its patho-genesis and a successful approach to curing the disease remain elusive. Increased research activity has greatly enhanced our understanding of the disease and led to new therapies that retard disease progression and improve patient ...
openaire +2 more sources
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
New England Journal of Medicine, 2023Mardi Gomberg-Maitland +2 more
exaly
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
American Journal of Respiratory and Critical Care Medicine, 2021Bradley A Maron +2 more
exaly
Treatment of Pulmonary Arterial Hypertension
New England Journal of Medicine, 2004Marc Humbert +2 more
exaly